Markets:

Overview

News

Currencies

International

Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

17.96 -0.39 (-2.13%)

Streaming Delayed Price Updated: 12:43 PM EDT, Apr 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET

May 19, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024 ↗

May 02, 2024

DYN stock results show that Dyne Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 02, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

March 27, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Recap: Dyne Therapeutics Q4 Earnings ↗

March 05, 2024

Via Benzinga

Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

March 27, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 25, 2024

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

Via Benzinga

Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday ↗

March 25, 2024

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.

Via Benzinga

Topics Stocks

Dyne Therapeutics Announces CEO Transition

March 25, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge ↗

March 14, 2024

Cantor Fitzgerald initiates coverage on Avidity Biosciences highlighting a robust pipeline led by del-desiran, a promising treatment for Myotonic dystrophy type 1. With strong management, proven...

Via Benzinga

Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days

March 13, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Chardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To Know ↗

March 08, 2024

Via Benzinga

Piper Sandler Maintains Overweight Rating for Dyne Therapeutics: Here's What You Need To Know ↗

March 06, 2024

Via Benzinga

DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023 ↗

March 05, 2024

DYN stock results show that Dyne Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

March 05, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday ↗

March 01, 2024

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Via Benzinga

Topics Stocks

Top 4 Health Care Stocks You May Want To Dump In February ↗

February 15, 2024

As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Via Benzinga

Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

February 14, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Present at February Investor Conferences

February 01, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

7 Speculative Stocks to Double Your Money THIS Year ↗

January 22, 2024

Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 15, 2024

Via Benzinga

$30M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗

January 12, 2024

Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades.

Via Benzinga

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

January 11, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

January 05, 2024

Shares of Applied Therapeutics, Inc.

Via Benzinga

Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 05, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

January 05, 2024

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday.

Via Benzinga

Topics Stocks

Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

January 04, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Crude Oil Moves Lower; Walgreens Posts Upbeat Earnings ↗

January 04, 2024

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining over 100 points on Thursday. The Dow traded up 0.33% to 37,554.56 while the NASDAQ fell 0.10% to 14,578.04. The S&P...

Via Benzinga

Topics Stocks

Dyne Therapeutics Inc. (NASDAQ: DYN) Leading the Way in Thursday Trading Based on Percentage Gain

January 04, 2024

Via Investor Brand Network

Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

January 04, 2024

Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.